About this author
Zack Lynch is author of The Neuro Revolution: How Brain Science Is Changing Our World (St. Martin's Press, July 2009).
He is the founder and executive director of the Neurotechnology Industry Organization (NIO) and co-founder of NeuroInsights. He serves on the advisory boards of the McGovern Institute for Brain Research at MIT, the Center for Neuroeconomic Studies, Science Progress, and SocialText, a social software company. Please send newsworthy items or feedback - to Zack Lynch.
Follow me on Twitter at @neurorev
Receive by email

TNRCoverWeb120.jpg Buy on Amazon
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

Brain Waves

« Socialtext Release Commerical Open Source Wiki | Main | Pretty Pearlescent Pills - Colorful Drugs Approved by FDA »

July 24, 2006

Translational Neurobiotech Developments Reviewed

Email This Entry

Posted by Zack Lynch

The July edition of Genetic Engineering News published an extensive review of a dozen CEO company presentations from the NeuroInsights' Neurotech Industry Investing conference in May. I recommend following the link to read the full review. Written by Gail Schechter, the article "Translational Medicine: Spotlighting Neurobiotech Developments Central Nervous System Remains a Large Target for Novel Therapies" highlights companies from several panels including: Targacept, Saegis Pharmaceuticals, Acumen Pharmaceuticals, Ceregene, Jazz Pharmaceuticals, Amarin, Predix Pharmaceuticals, BrainCells Inc., NeuroNova, Sound Pharmaceuticals, StemCells Inc., and StemCell Sciences.

116_Neurotech_Industry_Conference_-_May_18%2C_2006_Page_1_sm.jpgGail concludes, "Conference panelists, presenters, and participants alike were clearly favorably disposed toward neurotechnology, in spite of the unique challenges confronting CNS product development. Representatives from both venture capital and big pharma reported being open to funding neurotechnology, especially when a company’s products have already demonstrated proof-of-concept, are further along in clinical development, and have a clear commercialization path. High-risk is mitigated by the potential for significant reward. After all, today’s risks may be tomorrow’s breakthroughs."

If you missed this year's conference, mark your calendars for next year's two day Neurotech Industry Investing and Business Conference 2007 which will be held in San Francisco on May 17 and 18. If you are interested in speaking or sponsoring please contact me.

Comments (1) + TrackBacks (0) | Category: Neurotech Industry


1. Grant on July 26, 2006 11:18 PM writes...

"today’s risks may be tomorrow’s breakthroughs", I think a bold but an accurate statement. Without risks there is no stepping forward.

Permalink to Comment


Email this entry to:

Your email address:

Message (optional):

Chinese Cover of The Neuro Revolution
The Neuro Revolution Lands In China
How Neuroscience Will Change the World - My Interview on
Neuroscience Hearing on Capitol Hill Wednesday Sept 29, 2pm
The Neuro Revolution Published in Japan as "Neuro Wars"
Neurotech 2010: Translational Researchers Highlight Innovation
The Neuro Revolution in China Progressing
Speakers for Neurotech 2010 - Boston, May 19-20